MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF DABRAFENIB PLUS TRAMETINIB VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC BRAF V600 MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Tai, T. A. [1 ]
Perampaladas, K. [2 ]
Cooney, P. [1 ]
Mensah, L. [2 ]
Jameson, K. [2 ]
Rafia, R. [2 ]
Bains, R. [2 ]
Kane, N. [2 ]
机构：
[1] Novartis Global Serv Ctr, Dublin, Ireland
[2] Novartis Pharmaceut, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT35
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy plus /-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    LUNG CANCER, 2021, 155 : 175 - 182
  • [2] Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC
    Fan, Y.
    Jianying, Z.
    Yuanyuan, Z.
    Yan, Y.
    Nong, Y.
    Juan, L.
    Jialei, W.
    Jun, Z.
    Zhehai, W.
    Jun, C.
    Zhu, T.
    Li, H.
    Li, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S423 - S423
  • [3] Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
    Kreitman, Robert J.
    Moreau, Philippe
    Ravandi, Farhad
    Hutchings, Martin
    Gazzah, Anas
    Michallet, Anne-Sophie
    Wainberg, Zev A.
    Stein, Alexander
    Dietrich, Sascha
    de Jonge, Maja J. A.
    Willenbacher, Wolfgang
    De Greve, Jacques
    Arons, Evgeny
    Ilankumaran, Palanichamy
    Burgess, Paul
    Gasal, Eduard
    Subbiah, Vivek
    BLOOD, 2023, 141 (09) : 996 - 1006
  • [4] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [5] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
    Johal, Sukhvinder
    Miranda, Miguel
    Sarbajna, Tina
    Shi, Xiaojin
    Greystoke, Alastair
    Johnson, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
  • [6] Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)
    Hochmair, M. J.
    Nadal, E.
    D'yachkova, Y.
    Puri, T.
    Vickers, A.
    Wolowacz, S.
    Wang, X.
    Kiiskinen, U.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S62 - S63
  • [7] Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report
    Taniguchi, Yoshihiko
    Tamiya, Akihiro
    Yanagisawa, Atsushi
    Shimaya, Minako
    Kawakami, Mayu
    Inagaki, Yuji
    Saijo, Nobuhiko
    Matsuda, Yoshinobu
    Okishio, Kyoichi
    THORACIC CANCER, 2023, 14 (13) : 1201 - 1203
  • [8] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH ROS1 NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATED ANALYSIS
    Chu, P.
    Mitchell, C. R.
    Batson, S.
    Aziez, A.
    Antoniou, M.
    VALUE IN HEALTH, 2020, 23 : S423 - S424
  • [9] Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
    Janet Pan
    Clinical Drug Investigation, 2019, 39 : 1003 - 1007
  • [10] Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
    Pan, Janet
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 1003 - 1007
12345